// App-Quantinova.ai

TPS9106 : TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.

Researchers

Presenter

  • James Chih-Hsin Yang

Principal Investigators

  • Silvia Novello

  • Harry J.M. Groen

  • Maurice Perol

  • Enriqueta Felip

  • Frank Griesinger

  • Karen L. Reckamp

  • Jong-Seok Lee

  • Egbert F. Smit

  • Collin M. Blakely

  • Wallace L. Akerley

  • Young-Chul Kim

  • Lyudmila Bazhenova

  • Raffaele Califano

  • Richard Delmar Hall

  • Panayiotis Georgiou

  • Jeffrey D. Isaacson

  • Tony Golsorkhi

  • Heather A. Wakelee

Medical Centers

  • National Taiwan University Hospital, Taipei City, Taiwan

  • The Royal Marsden Hospital, London, United Kingdom

  • University of Turin, AOU San Luigi, Orbassano, Italy

  • Universitair Medisch Centrum Groningen, Groningen, Netherlands

  • Centre Leon Berard, Lyon, France

  • Vall d'Hebron Institute of Oncology, Barcelona, Spain

  • Pius Hospital Oldenburg, Oldenburg, Germany

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • VU University Medical Center, Amsterdam, Netherlands

  • University of California, San Francisco, San Francisco, CA

  • University of Utah Healthcare, Huntsman Cancer Hospital, Salt Lake City, UT

  • University of California, San Diego, La Jolla, CA

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • University of Virginia Medical Center, Charlottesville, VA

  • Clovis Oncology, Inc., Boulder, CO

  • Clovis Oncology, Inc., Boulder, CO

  • Stanford Univeresity Medical Center, Stanford, CA

Locations

  • Taiwan

  • Italy

  • Netherlands

  • Spain

  • Germany

  • United Kingdom

  • United States

  • France

Companies

  • Clovis Oncology, Inc

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

  • Brain metastasis

  • Lung Cancer

  • Solid malignancies

Biomarkers

  • Epidermal growth factor receptor

Drug/Treatment

  • rociletinib

  • L-Tyrosine

Outcome

  • N/A

Study Design

  • Randomized

  • Cross Over

  • Open Label

  • Multinational

Phase

  • III

Study Id's

  • NCT02322281

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved